Pesquisas alternativas:
camp » cam (Expandir a Pesquisa), cap (Expandir a Pesquisa), came (Expandir a Pesquisa)
comp » com (Expandir a Pesquisa), como (Expandir a Pesquisa), come (Expandir a Pesquisa)
compared » comared (Expandir a Pesquisa), comoared (Expandir a Pesquisa), comeared (Expandir a Pesquisa)
nart » nacrt (Expandir a Pesquisa), nat (Expandir a Pesquisa), nar (Expandir a Pesquisa)
momany » momani (Expandir a Pesquisa), romany (Expandir a Pesquisa)
none » non (Expandir a Pesquisa)
camp » cam (Expandir a Pesquisa), cap (Expandir a Pesquisa), came (Expandir a Pesquisa)
comp » com (Expandir a Pesquisa), como (Expandir a Pesquisa), come (Expandir a Pesquisa)
compared » comared (Expandir a Pesquisa), comoared (Expandir a Pesquisa), comeared (Expandir a Pesquisa)
nart » nacrt (Expandir a Pesquisa), nat (Expandir a Pesquisa), nar (Expandir a Pesquisa)
momany » momani (Expandir a Pesquisa), romany (Expandir a Pesquisa)
none » non (Expandir a Pesquisa)
1
“... associated with these cytotoxic agents. nab-paclitaxel is a solvent free, albumin-bound 130-nanometer...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
2
Por Blomstrand, Hakon, Scheibling, Ursula, Bratthäll, Charlotte, Green, Henrik, Elander, Nils O.
Publicado no BMC Cancer (2019)
“... (Gem/NabP) showed increased overall survival compared to gemcitabine alone in the treatment of advanced...”Publicado no BMC Cancer (2019)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
3
Por Ozaki, Daniel A., Gao, Hongmei, Todd, Christopher A., Greene, Kelli M., Montefiori, David C., Sarzotti-Kelsoe, Marcella
Publicado em 2012
“... compliance. Furthermore, using a newly established external proficiency testing program for the TZM-bl NAb...”Publicado em 2012
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
4
Por Dranitsaris, George, Yu, Bo, King, Jennifer, Kaura, Satyin, Zhang, Adams
Publicado no Clinicoecon Outcomes Res (2015)
“... for the key stakeholders, a cost-utility analysis comparing nab-paclitaxel to docetaxel, both as alternatives...”Publicado no Clinicoecon Outcomes Res (2015)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
5
Por Chen, Yi, Li, Jinyu, Chen, Shixue, Zhang, Yibao, Hu, Yi, Zhang, Guoqing, Yan, Xiang, Jiao, Shunchang
Publicado no Sci Rep (2017)
“...-PC and docetaxel remained unclear until now. This retrospective study aimed to compare the efficacy...”Publicado no Sci Rep (2017)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
6
Por Wang, Jianfu J., Zhang, Nan, Richardson, Sarah A., Wu, Jin V.
Publicado no Expert Rev Mol Diagn (2021)
“... of POCTs have been developed and are commercially available now. They are designed to detect either a SARS...”Publicado no Expert Rev Mol Diagn (2021)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
7
Por Kawamoto, Yasuyuki, Komatsu, Yoshito, Yuki, Satoshi, Sawada, Kentaro, Muranaka, Tetsuhito, Harada, Kazuaki, Nakatsumi, Hiroshi, Fukushima, Hiraku, Ishiguro, Atsushi, Dazai, Masayoshi, Hatanaka, Kazuteru, Nakamura, Michio, Iwanaga, Ichiro, Uebayashi, Minoru, Sogabe, Susumu, Kobayashi, Yoshimitsu, Miyagishima, Takuto, Ono, Kota, Sakamoto, Naoya, Sakata, Yuh
Publicado no BMC Cancer (2017)
“... with advanced gastric cancer. Moreover, the S-1 plus oxaliplatin regimen is now a standard treatment. Nab...”Publicado no BMC Cancer (2017)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
8
Efficacy and safety of PD-1/PD-L1 inhibitors plus nab-paclitaxel for patients with non-small cell...
Por Zhang, Fan, Huang, Di, Zhao, Lei, Li, Tao, Zhang, Sujie, Zhang, Guoqing, Yuan, Fang, Zhang, Jie, Zhang, Yuzi, Zhao, Zhengyi, Cui, Longgang, Zhao, Jing, Wang, Guoqiang, Cai, Shangli, Bai, Yuezong, Wang, Jinliang, Hu, Yi
Publicado no Ther Adv Med Oncol (2020)
“... with anti-PD-1/PD-L1 monotherapy and 17 were treated with anti-PD-1/PD-L1 plus nab-paclitaxel. With a median...”Publicado no Ther Adv Med Oncol (2020)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
9
Por Oguntuyo, Kasopefoluwa Y., Stevens, Christian S., Hung, Chuan-Tien, Ikegame, Satoshi, Acklin, Joshua A., Kowdle, Shreyas S., Carmichael, Jillian C., Chiu, Hsin-Ping, Azarm, Kristopher D., Haas, Griffin D., Amanat, Fatima, Klingler, Jéromine, Baine, Ian, Arinsburg, Suzanne, Bandres, Juan C., Siddiquey, Mohammed N.A., Schilke, Robert M., Woolard, Matthew D., Zhang, Hongbo, Duty, Andrew J., Kraus, Thomas A., Moran, Thomas M., Tortorella, Domenico, Lim, Jean K., Gamarnik, Andrea V., Hioe, Catarina E., Zolla-Pazner, Susan, Ivanov, Stanimir S., Kamil, Jeremy P., Krammer, Florian, Lee, Benhur
Publicado no medRxiv (2020)
“... these limitations, we developed a standardized VNA using VSVΔG-based CoV-2-S pseudotyped particles (CoV2pp) that can...”Publicado no medRxiv (2020)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
10
Por Hutchinson, Jennie M., Mesa, Kathryn A., Alexander, David L., Yu, Bin, O'Rourke, Sara M., Limoli, Kay L., Wrin, Terri, Deeks, Steven G., Berman, Phillip W.
Publicado no Front Immunol (2019)
“... recovered from these individuals may more closely resemble the Envs that gave rise to bNAbs compared...”Publicado no Front Immunol (2019)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
11
Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16...
Por Einstein, Mark H, Baron, Mira, Levin, Myron J, Chatterjee, Archana, Fox, Bradley, Scholar, Sofia, Rosen, Jeffrey, Chakhtoura, Nahida, Meric, Dorothée, Dessy, Francis J, Datta, Sanjoy K, Descamps, Dominique, Dubin, Gary
Publicado em 2011
“...). Month 7 results were previously reported; we now report Month 24 results. In the according-to-protocol...”Publicado em 2011
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
12
Por Gao, Yue, Nai, Jingxue, Yang, Zhenbo, Zhang, Jinbang, Ma, Siyu, Zhao, Yumei, Li, Hui, Li, Jiaxin, Yang, Yang, Yang, Meiyan, Wang, Yuli, Gong, Wei, Yu, Fanglin, Gao, Chunsheng, Li, Zhiping, Mei, Xingguo
Publicado no PLoS One (2021)
“... and self-made nanoparticles. In a word, our novel preparative method for nab paclitaxel can significantly...”Publicado no PLoS One (2021)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
13
“... approaches in RPC. We need studies that compare the two approaches and can identify the appropriate sequence...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
14
“... and disadvantages of the two therapeutic approaches in RPC. We need studies that compare the two approaches and can...”
Obter o texto integral
Obter o texto integral
Artigo
15
Por Bandyopadhyay, Ananda S., Asturias, Edwin J., O'Ryan, Miguel, Oberste, M. Steven, Weldon, William, Clemens, Ralf, Rüttimann, Ricardo, Modlin, John F., Gast, Chris
Publicado no Vaccine (2017)
“...) lower for subjects with NAb titers at the ULOQ as compared with LLOQ on day of challenge. Overall...”Publicado no Vaccine (2017)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
16
Por Martín, Andrés Muñoz, Hidalgo, Manuel, Alvarez, Rafael, Arrazubi, Virginia, Martínez-Galán, Joaquina, Salgado, Mercedes, Macarulla, Teresa, Carrato, Alfredo
Publicado no J Cancer (2018)
“... in overall survival when compared to GEM alone. Treatment guidelines now recommend either one of these two...”Publicado no J Cancer (2018)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
17
Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Primary African Isolates
Por Lorenzi, Julio C. C., Mendoza, Pilar, Cohen, Yehuda Z., Nogueira, Lilian, Lavine, Christy, Sapiente, Joseph, Wiatr, Marie, Mugo, Nelly R., Mujugira, Andrew, Delany, Sinead, Lingappa, Jairam, Celum, Connie, Seaman, Michael S., Caskey, Marina, Nussenzweig, Michel C.
Publicado no J Virol (2021)
“... activity of 9 anti-HIV-1 bNAbs now in clinical development against 126 clade A, C, and D peripheral blood...”Publicado no J Virol (2021)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
18
Por Han, Nayoung, Kim, Hannah, Min, Soo Kee, Paek, Sun-Ha, Park, Chul-Kee, Choi, Seung-Hong, Chae, U-Ri, Park, Sung-Hye
Publicado no J Pathol Transl Med (2016)
“... (HPC), because <i>NAB2-STAT6</i> gene fusion has been observed in both intracranial and extracranial...”Publicado no J Pathol Transl Med (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
19
Por Xi, Jing, Oza, Aabha, Thomas, Shana, Naughton, Michael, Ademuyiwa, Foluso, Weilbaecher, Katherine, Suresh, Rama, Bose, Ron, Cherian, Mathew, Hernandez-Aya, Leonel, Frith, Ashley, Peterson, Lindsay, Luo, Jingqin, Krishnamurthy, Jairam, Ma, Cynthia X.
Publicado no J Natl Compr Canc Netw (2019)
“... to compare differences. RESULTS: Two-hundred patients, with a median age of 59.4 years and a follow-up...”Publicado no J Natl Compr Canc Netw (2019)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
20
Por Chiem, Kevin, Morales Vasquez, Desarey, Park, Jun-Gyu, Platt, Roy Neal, Anderson, Tim, Walter, Mark R., Kobie, James J., Ye, Chengjin, Martinez-Sobrido, Luis
Publicado no J Virol (2021)
“... for the treatment of SARS-CoV-2, where reporter gene expression can be used as a valid surrogate to track viral...”Publicado no J Virol (2021)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo